Exclusive deal : 20% Instant discount on Direct purchases! Don't wait—claim your discount today!
This report aims to provide a comprehensive presentation of the global market for Tumor Immunity Therapy study by Market Intellix gives insights concerning the market elements influencing the market, Market scope, Market division, and overlays shadow upon the leading market players featuring the positive cutthroat scene and patterns beating the years.
Global Tumor Immunity Therapy Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Tumor Immunity Therapy market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Immune Checkpoint Inhibitor Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Tumor Immunity Therapy include Bristol-Myers Squibb, Merck & Co., Inc., Roche AG, AstraZeneca, Plc, Sanofi S.A., Dendreon Pharmaceuticals, Novartis, Gilead Sciences Inc. and IMVAQ Therapeutics, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
The study provides the Tumor Immunity Therapy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Segmental Outline:
Global Tumor Immunity Therapy Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Tumor Immunity Therapy Market Segment Percentages, by Type, 2021 (%)
Immune Checkpoint Inhibitor
Cytokine Immunotherapy
Cancer Vaccine
Car-t Cell Therapy
Others
Global Tumor Immunity Therapy Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Tumor Immunity Therapy Market Segment Percentages, by Application, 2021 (%)
Hospital
Clinic
Global Tumor Immunity Therapy Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Tumor Immunity Therapy Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Tumor Immunity Therapy revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Tumor Immunity Therapy revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Bristol-Myers Squibb
Merck & Co., Inc.
Roche AG
AstraZeneca, Plc
Sanofi S.A.
Dendreon Pharmaceuticals
Novartis
Gilead Sciences Inc.
IMVAQ Therapeutics
Arch Oncology
Juno Therapeutics
Refuge
Lepu Biopharma
Genoimmune
TCR Cure
This Report Addresses:
– Market Intelligence enables effective decision-making
– Market estimates and forecasts from 2022 to 2028
– Growth opportunities and trend analysis
– Segment and regional revenue forecast for market evaluation
– Competitive strategy and analysis of market segments
– List of product innovations to stay on top.
– The impact of COVID-19 and how to survive in these fast-growing markets.
1 Introduction to Research & Analysis Reports
1.1 Tumor Immunity Therapy Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Tumor Immunity Therapy Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Tumor Immunity Therapy Overall Market Size
2.1 Global Tumor Immunity Therapy Market Size: 2021 VS 2028
2.2 Global Tumor Immunity Therapy Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Tumor Immunity Therapy Players in Global Market
3.2 Top Global Tumor Immunity Therapy Companies Ranked by Revenue
3.3 Global Tumor Immunity Therapy Revenue by Companies
3.4 Top 3 and Top 5 Tumor Immunity Therapy Companies in Global Market, by Revenue in 2021
3.5 Global Companies Tumor Immunity Therapy Product Type
3.6 Tier 1, Tier 2 and Tier 3 Tumor Immunity Therapy Players in Global Market
3.6.1 List of Global Tier 1 Tumor Immunity Therapy Companies
3.6.2 List of Global Tier 2 and Tier 3 Tumor Immunity Therapy Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type - Global Tumor Immunity Therapy Market Size Markets, 2021 & 2028
4.1.2 Immune Checkpoint Inhibitor
4.1.3 Cytokine Immunotherapy
4.1.4 Cancer Vaccine
4.1.5 Car-t Cell Therapy
4.1.6 Others
4.2 By Type - Global Tumor Immunity Therapy Revenue & Forecasts
4.2.1 By Type - Global Tumor Immunity Therapy Revenue, 2017-2022
4.2.2 By Type - Global Tumor Immunity Therapy Revenue, 2023-2028
4.2.3 By Type - Global Tumor Immunity Therapy Revenue Market Share, 2017-2028
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Tumor Immunity Therapy Market Size, 2021 & 2028
5.1.2 Hospital
5.1.3 Clinic
5.2 By Application - Global Tumor Immunity Therapy Revenue & Forecasts
5.2.1 By Application - Global Tumor Immunity Therapy Revenue, 2017-2022
5.2.2 By Application - Global Tumor Immunity Therapy Revenue, 2023-2028
5.2.3 By Application - Global Tumor Immunity Therapy Revenue Market Share, 2017-2028
6 Sights by Region
6.1 By Region - Global Tumor Immunity Therapy Market Size, 2021 & 2028
6.2 By Region - Global Tumor Immunity Therapy Revenue & Forecasts
6.2.1 By Region - Global Tumor Immunity Therapy Revenue, 2017-2022
6.2.2 By Region - Global Tumor Immunity Therapy Revenue, 2023-2028
6.2.3 By Region - Global Tumor Immunity Therapy Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Tumor Immunity Therapy Revenue, 2017-2028
6.3.2 US Tumor Immunity Therapy Market Size, 2017-2028
6.3.3 Canada Tumor Immunity Therapy Market Size, 2017-2028
6.3.4 Mexico Tumor Immunity Therapy Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Tumor Immunity Therapy Revenue, 2017-2028
6.4.2 Germany Tumor Immunity Therapy Market Size, 2017-2028
6.4.3 France Tumor Immunity Therapy Market Size, 2017-2028
6.4.4 U.K. Tumor Immunity Therapy Market Size, 2017-2028
6.4.5 Italy Tumor Immunity Therapy Market Size, 2017-2028
6.4.6 Russia Tumor Immunity Therapy Market Size, 2017-2028
6.4.7 Nordic Countries Tumor Immunity Therapy Market Size, 2017-2028
6.4.8 Benelux Tumor Immunity Therapy Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Tumor Immunity Therapy Revenue, 2017-2028
6.5.2 China Tumor Immunity Therapy Market Size, 2017-2028
6.5.3 Japan Tumor Immunity Therapy Market Size, 2017-2028
6.5.4 South Korea Tumor Immunity Therapy Market Size, 2017-2028
6.5.5 Southeast Asia Tumor Immunity Therapy Market Size, 2017-2028
6.5.6 India Tumor Immunity Therapy Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Tumor Immunity Therapy Revenue, 2017-2028
6.6.2 Brazil Tumor Immunity Therapy Market Size, 2017-2028
6.6.3 Argentina Tumor Immunity Therapy Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Tumor Immunity Therapy Revenue, 2017-2028
6.7.2 Turkey Tumor Immunity Therapy Market Size, 2017-2028
6.7.3 Israel Tumor Immunity Therapy Market Size, 2017-2028
6.7.4 Saudi Arabia Tumor Immunity Therapy Market Size, 2017-2028
6.7.5 UAE Tumor Immunity Therapy Market Size, 2017-2028
7 Players Profiles
7.1 Bristol-Myers Squibb
7.1.1 Bristol-Myers Squibb Corporate Summary
7.1.2 Bristol-Myers Squibb Business Overview
7.1.3 Bristol-Myers Squibb Tumor Immunity Therapy Major Product Offerings
7.1.4 Bristol-Myers Squibb Tumor Immunity Therapy Revenue in Global Market (2017-2022)
7.1.5 Bristol-Myers Squibb Key News
7.2 Merck & Co., Inc.
7.2.1 Merck & Co., Inc. Corporate Summary
7.2.2 Merck & Co., Inc. Business Overview
7.2.3 Merck & Co., Inc. Tumor Immunity Therapy Major Product Offerings
7.2.4 Merck & Co., Inc. Tumor Immunity Therapy Revenue in Global Market (2017-2022)
7.2.5 Merck & Co., Inc. Key News
7.3 Roche AG
7.3.1 Roche AG Corporate Summary
7.3.2 Roche AG Business Overview
7.3.3 Roche AG Tumor Immunity Therapy Major Product Offerings
7.3.4 Roche AG Tumor Immunity Therapy Revenue in Global Market (2017-2022)
7.3.5 Roche AG Key News
7.4 AstraZeneca, Plc
7.4.1 AstraZeneca, Plc Corporate Summary
7.4.2 AstraZeneca, Plc Business Overview
7.4.3 AstraZeneca, Plc Tumor Immunity Therapy Major Product Offerings
7.4.4 AstraZeneca, Plc Tumor Immunity Therapy Revenue in Global Market (2017-2022)
7.4.5 AstraZeneca, Plc Key News
7.5 Sanofi S.A.
7.5.1 Sanofi S.A. Corporate Summary
7.5.2 Sanofi S.A. Business Overview
7.5.3 Sanofi S.A. Tumor Immunity Therapy Major Product Offerings
7.5.4 Sanofi S.A. Tumor Immunity Therapy Revenue in Global Market (2017-2022)
7.5.5 Sanofi S.A. Key News
7.6 Dendreon Pharmaceuticals
7.6.1 Dendreon Pharmaceuticals Corporate Summary
7.6.2 Dendreon Pharmaceuticals Business Overview
7.6.3 Dendreon Pharmaceuticals Tumor Immunity Therapy Major Product Offerings
7.6.4 Dendreon Pharmaceuticals Tumor Immunity Therapy Revenue in Global Market (2017-2022)
7.6.5 Dendreon Pharmaceuticals Key News
7.7 Novartis
7.7.1 Novartis Corporate Summary
7.7.2 Novartis Business Overview
7.7.3 Novartis Tumor Immunity Therapy Major Product Offerings
7.7.4 Novartis Tumor Immunity Therapy Revenue in Global Market (2017-2022)
7.7.5 Novartis Key News
7.8 Gilead Sciences Inc.
7.8.1 Gilead Sciences Inc. Corporate Summary
7.8.2 Gilead Sciences Inc. Business Overview
7.8.3 Gilead Sciences Inc. Tumor Immunity Therapy Major Product Offerings
7.8.4 Gilead Sciences Inc. Tumor Immunity Therapy Revenue in Global Market (2017-2022)
7.8.5 Gilead Sciences Inc. Key News
7.9 IMVAQ Therapeutics
7.9.1 IMVAQ Therapeutics Corporate Summary
7.9.2 IMVAQ Therapeutics Business Overview
7.9.3 IMVAQ Therapeutics Tumor Immunity Therapy Major Product Offerings
7.9.4 IMVAQ Therapeutics Tumor Immunity Therapy Revenue in Global Market (2017-2022)
7.9.5 IMVAQ Therapeutics Key News
7.10 Arch Oncology
7.10.1 Arch Oncology Corporate Summary
7.10.2 Arch Oncology Business Overview
7.10.3 Arch Oncology Tumor Immunity Therapy Major Product Offerings
7.10.4 Arch Oncology Tumor Immunity Therapy Revenue in Global Market (2017-2022)
7.10.5 Arch Oncology Key News
7.11 Juno Therapeutics
7.11.1 Juno Therapeutics Corporate Summary
7.11.2 Juno Therapeutics Business Overview
7.11.3 Juno Therapeutics Tumor Immunity Therapy Major Product Offerings
7.11.4 Juno Therapeutics Tumor Immunity Therapy Revenue in Global Market (2017-2022)
7.11.5 Juno Therapeutics Key News
7.12 Refuge
7.12.1 Refuge Corporate Summary
7.12.2 Refuge Business Overview
7.12.3 Refuge Tumor Immunity Therapy Major Product Offerings
7.12.4 Refuge Tumor Immunity Therapy Revenue in Global Market (2017-2022)
7.12.5 Refuge Key News
7.13 Lepu Biopharma
7.13.1 Lepu Biopharma Corporate Summary
7.13.2 Lepu Biopharma Business Overview
7.13.3 Lepu Biopharma Tumor Immunity Therapy Major Product Offerings
7.13.4 Lepu Biopharma Tumor Immunity Therapy Revenue in Global Market (2017-2022)
7.13.5 Lepu Biopharma Key News
7.14 Genoimmune
7.14.1 Genoimmune Corporate Summary
7.14.2 Genoimmune Business Overview
7.14.3 Genoimmune Tumor Immunity Therapy Major Product Offerings
7.14.4 Genoimmune Tumor Immunity Therapy Revenue in Global Market (2017-2022)
7.14.5 Genoimmune Key News
7.15 TCR Cure
7.15.1 TCR Cure Corporate Summary
7.15.2 TCR Cure Business Overview
7.15.3 TCR Cure Tumor Immunity Therapy Major Product Offerings
7.15.4 TCR Cure Tumor Immunity Therapy Revenue in Global Market (2017-2022)
7.15.5 TCR Cure Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
Research Methodology:
Tumor Immunity Therapy Market Size Estimation
To estimate market size and trends, we use a combination of top-down and bottom-up methods. This allows us to evaluate the market from various perspectives—by company, region, product type, and end users.
Our estimates are based on actual sales data, excluding any discounts. Segment breakdowns and market shares are calculated using weighted averages based on usage rates and average prices. Regional insights are determined by how widely a product or service is adopted in each area.
Key companies are identified through secondary sources like industry reports and company filings. We then verify revenue estimates and other key data points through primary research, including interviews with industry experts, company executives, and decision-makers.
We take into account all relevant factors that could influence the market and validate our findings with real-world input. Our final insights combine both qualitative and quantitative data to provide a well-rounded view. Please note, these estimates do not account for unexpected changes such as inflation, economic downturns, or policy shifts.
Data Source
Secondary Sources
This study draws on a wide range of secondary sources, including press releases, annual reports, non-profit organizations, industry associations, government agencies, and customs data. We also referred to reputable databases and directories such as Bloomberg, Wind Info, Hoovers, Factiva, Trading Economics, Statista, and others. Additional references include investor presentations, company filings (e.g., SEC), economic data, and documents from regulatory and industry bodies.
These sources were used to gather technical and market-focused insights, identify key players, analyze market segmentation and classification, and track major trends and developments across industries.
| Market Size |
|
|
| Market Position of Top Company |
|
|
| Qualitative Analysis |
|
|
Primary Sources
As part of our primary research, we interviewed a variety of stakeholders from both the supply and demand sides to gather valuable qualitative and quantitative insights.
On the supply side, we spoke with product manufacturers, competitors, industry experts, research institutions, distributors, traders, and raw material suppliers. On the demand side, we engaged with business leaders, marketing and sales heads, technology and innovation directors, supply chain executives, and end users across key organizations.
These conversations helped us better understand market segmentation, pricing, applications, leading players, supply chains, demand trends, industry outlook, and key market dynamics—including risks, opportunities, barriers, and strategic developments.
Key Data Information from Primary Sources
| Primary Sources | Parameters | Key Data |
| Market Segments(by Application, by Type) |
|
|
| Total Market |
|
|